The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,761.00
Bid: 1,757.50
Ask: 1,758.00
Change: 27.50 (1.59%)
Spread: 0.50 (0.028%)
Open: 1,736.00
High: 1,767.00
Low: 1,736.00
Prev. Close: 1,733.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

WINNERS & LOSERS SUMMARY: McColl's Retail Sinks After Profit Slumps

Mon, 23rd Jul 2018 10:23

LONDON (Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Monday.----------FTSE 100 - WINNERS----------GlaxoSmithKline, up 0.5%. The pharmaceutical company is considering splitting the pharmaceutical company due to pressure from investors, the Financial Times reported late on Friday. According to the newspaper, "several top-ten investors" have been urging the company's board to spin off Glaxo's consumer division. According to a newspaper source, Chairman Philip Hampton has been in talks over the possible creation of a stand-alone pharmaceuticals and vaccines company.----------FTSE 100 - LOSERS----------easyJet, down 1.8%, International Consolidated Airlines Group, down 1.7%. The airlines were suffering a negative read-across from peer Ryanair Holdings' first quarter results. The Irish carrier said lower fares, the earlier timing of Easter, and higher fuel and pilot costs resulted in a 20% drop in first quarter profit. Ryanair said it remains concerned by the danger of a hard, or no-deal, Brexit and may be forced to restrict the voting rights of all non-EU shareholders in the event of a hard Brexit, to ensure that Ryanair remains majority owned and controlled by European Union shareholders. For the three months ended June 30, the airline recorded profit after tax of EUR319 million, down from EUR397 million in the comparative year ago period, on a revenue of EUR2.08 billion and EUR1.91 billion, respectively. Ryanair shares were down 5.2%. Midcap peer Wizz Air was down 2.5%.----------Hargreaves Lansdown, down 1.0%. The fund supermarket was cut to Underperform from Hold by Jefferies. ----------FTSE 250 - LOSERS----------Ascential, down 4.2%. The business events organiser said lower margins and earnings for its core exhibitions and festivals business led to a drop in first half profit. Ascential recorded pretax profit of GBP23.1 million for the six months ended June 30, down 14% from GBP26.8 million in the comparative period a year ago, on revenue of GBP188.9 million and GBP165.1 million, respectively. Group margins dipped to 32.0% from 36.8%. Exhibitions & Festivals margins fell to 49.7% from 55.5%, while information services unit recorded margins of 25.1% versus 28.8%. Adjusted earnings before interest, taxes, depreciation and amortisation dipped to GBP60.4 million from GBP60.8 million. ----------OTHER MAIN MARKET AND AIM - WINNERS----------Keras Resources, up 18%. The miner said it has secured permission to undertake a bulk sampling metallurgical testwork programme at the Nayega manganese project in northern Togo. Keras said the bulk sampling will include processing of 10,000 tonnes of beneficiated manganese ore, by a major producer of manganese-based alloys, for large scale metallurgical testwork, to assess the suitability of the ore in their manganese smelting facilities. The test work is estimated to cost USD1.5 million and will be fully funded by the unnamed third-party manganese end-user. Keras Resources is targeting a 10 millimetre to 75 mm manganese product from a simplified washing, scrubbing and screening operation. This will provide real-time data with respect to the operating costs and logistics of exporting beneficiated manganese to third party end-users, the company said.----------OTHER MAIN MARKET AND AIM - LOSERS----------McColl's Retail Group, down 12%. The convenience store chain said first half profit nearly halved on the back of supply chain disruptions. For the 26 weeks ended May 28, McColl's reported pretax profit of GBP2.3 million, down from GBP4.5 million for the same period the year before. The drop in profit was primarily attributed to costs relating to the collapse of wholesaler Palmer & Harvey, health and safety breach fines and an unprofitable store closure programme. First half like-for-likes sales were down 2.7% due to supply chain disruption caused by the demise of Palmer & Harvey. The company separately said Chief Financial Officer Simon Fuller will be leaving the company to join newspaper publisher Reach in the same role. In addition, Liberum cut the stock to Hold from Buy. ----------
More News
7 May 2024 09:51

LONDON BROKER RATINGS: AstraZeneca target raised; Antofagasta lowered

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Friday:

Read more
2 May 2024 19:57

GSK knew about Zantac cancer risk, attorneys tell jury in first trial

May 2 (Reuters) - U.S. attorneys for a woman who claims her colon cancer was caused by the now discontinued heartburn drug Zantac on Thursday told a jury in Chicago that pharmaceutical companies GSK and Boehringer Ingelheim knew the product could cause cancer if it was not handled properly but failed to warn the public.

Read more
2 May 2024 09:48

LONDON BROKER RATINGS: Deutsche Bank likes TP ICAP but says sell CMC

(Alliance News) - The following London-listed shares received analyst recommendations Thursday morning and Wednesday:

Read more
1 May 2024 19:39

Bird flu testing shows more dairy products are safe, US FDA says

CHICAGO, May 1 (Reuters) - Preliminary results of tests on additional dairy products show that pasteurization inactivates the bird flu virus, the U.S. Food and Drug Administration said on Wednesday.

Read more
1 May 2024 17:31

UK's FTSE 100 slips ahead of Fed outcome, energy stocks weigh

FTSE 100 down 0.3%, FTSE 250 off 0.2%

*

Read more
1 May 2024 16:56

LONDON MARKET CLOSE: FTSE 100 down ahead of US interest rate decision

(Alliance News) - Stock prices in London closed mostly in the red on Wednesday, as investors eye the latest interest rate decision from the US Federal Reserve this evening.

Read more
1 May 2024 16:42

London close: Stocks fall ahead of US Fed decision

(Sharecast News) - London markets closed lower on Wednesday, as investors digested the latest UK manufacturing data and anticipated an impending policy announcement from the US Federal Reserve.

Read more
1 May 2024 11:55

LONDON MARKET MIDDAY: FTSE 100 treads water as Fed takes centre-stage

(Alliance News) - London's FTSE 100 traded off session highs heading into Wednesday afternoon, as some pre-Federal Reserve decision nerves kicked in.

Read more
1 May 2024 10:54

GSK raises profit outlook on strong vaccine, HIV drug sales

FY profit forecast raised to 8-10%

*

Read more
1 May 2024 08:57

LONDON MARKET OPEN: FTSE 100 shakes off New York slump before Fed

(Alliance News) - Stock prices in London opened mixed on Wednesday, with the FTSE 100 brushing off some pre-Federal Reserve decision trepidation to record an early rise, while the dollar climbed on the expectation that Jerome Powell will sound hawkish in his press conference later.

Read more
1 May 2024 08:50

TOP NEWS: GSK expects momentum to continue after strong first quarter

(Alliance News) - GSK PLC on Wednesday raised its annual earnings forecast, and said it expects sales growth at the top-end of guidance, after a "strong" start to the year.

Read more
1 May 2024 07:46

LONDON BRIEFING: GSK ups outlook; Next first-quarter beats forecast

(Alliance News) - Equities in London are called to open flat on Wednesday, ahead of the latest Federal Reserve interest rate decision, while a host of financial markets in mainland Europe and beyond are closed for public holidays.

Read more
1 May 2024 07:36

GSK lifts annual guidance on strong virus treatment sales

(Sharecast News) - UK pharmaceutical giant GSK lifted annual profits guidance on Wednesday, as it pinned its hopes on demand for its respiratory virus and shingles treatments.

Read more
30 Apr 2024 23:46

First trial over Zantac cancer claims set to begin in Chicago

April 30 (Reuters) - The first trial over claims that blockbuster heartburn drug Zantac, once sold by GSK and other companies, causes cancer is set to begin this week in Chicago.

Read more
30 Apr 2024 22:39

First trial over Zantac cancer claims set to begin in Chicago

April 30 (Reuters) - The first trial over claims that blockbuster heartburn drug Zantac, once sold by GSK and other companies, causes cancer is set to begin this week in Chicago.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.